| DC23004 |
PSMA-ligand-1
Featured
|
PSMA ligand-tubulysin compounds represent a cutting-edge approach to targeted cancer therapy, combining the precision of PSMA targeting with the potent cytotoxicity of tubulysin. This strategy holds significant promise for improving outcomes in prostate cancer and other PSMA-expressing malignancies, offering a highly specific and effective treatment option with reduced systemic toxicity. As research progresses, these compounds could play a transformative role in the field of oncology. |
|
| DC12287 |
delta-Valerobetaine
Featured
|
Delta-Valerobetaine is a precursor of trimethylamine N-oxide (TMAO). |
|
| DC12162 |
PSMA-617
Featured
|
PSMA-617 is a high potent prostate-specific membrane antigen (PSMA) inhibitor, with a Ki of 0.37 nM. |
|
| DC33611 |
PSMA-617 Linker
Featured
|
Vipivotide tetraxetan Ligand-Linker Conjugate (PSMA-617 Ligand-Linker Conjugate) is widely used in the treatment of metastatic castration-resistant prostate cancer (mCRPC) due to its ability to deliver targeted radiation directly to PSMA-expressing cancer cells, minimizing damage to surrounding healthy tissues. |
|
| DC40061 |
DOTATATE
Featured
|
DOTATATE is a powerful tool in nuclear medicine, enabling the diagnosis and treatment of somatostatin receptor-positive tumors, particularly neuroendocrine tumors. When labeled with radionuclides like Ga-68 or Lu-177, it provides highly sensitive imaging and targeted therapy, making it a cornerstone in the management of these cancers. Its theragnostic potential allows for personalized treatment strategies, improving patient outcomes.
|
|
| DC60103 |
PSMA11
Featured
|
PSMA-11 is a critical tool in nuclear medicine, enabling the synthesis of Ga-68-PSMA-11 for PET imaging of PSMA-expressing tumors. Its high specificity for PSMA, combined with the favorable properties of Ga-68, makes it a valuable diagnostic agent in the management of prostate cancer and potentially other malignancies. |
|
| DC46535 |
THK-5475(THK 5475)
Featured
|
THK-5475(THK5475) is a precursor of THK-5470, a monoamine oxidase-B(MAO-B) imaging probe, could be used for neurological diseases study (from patent EP2019-846498). |
|
| DC50044 |
Edotreotide
Featured
|
Edotreotide is a synthetic somatostatin analogue that is used in nuclear medicine for the diagnosis and research of certain types of cancers, particularly neuroendocrine tumors (NETs). Somatostatin is a peptide hormone that inhibits the release of several other hormones, and many neuroendocrine tumors overexpress somatostatin receptors (SSTRs), making them ideal targets for somatostatin analogues like edotreotide. |
|
| DC71440 |
FAP-2286
Featured
|
FAP-2286 is a highly promising FAP-targeting theranostic agent with potent affinity for FAP, versatile radionuclide coupling capabilities, and demonstrated antitumor activity. Its ability to serve as both a diagnostic imaging agent and a therapeutic tool makes it a valuable asset in oncology, particularly for cancers with prominent stromal involvement. As research progresses, FAP-2286 has the potential to significantly advance cancer diagnosis, treatment, and research, offering new hope for patients with FAP-expressing tumors. |
|
| DC65336 |
PSMA-1007
Featured
|
PSMA-1007 is a novel Glu-Ureido-based prostate-specific membrane antigen (PSMA) inhibitor designed for use in positron emission tomography (PET) imaging of prostate cancer. It belongs to the class of small-molecule PSMA inhibitors that specifically target PSMA, a transmembrane protein highly expressed in prostate cancer cells and the neovasculature of other solid tumors. PSMA-1007 is particularly notable for its favorable pharmacokinetic properties, including high tumor uptake and low urinary excretion, making it an excellent tool for prostate cancer diagnosis and staging. |
.gif)
|
| DC65338 |
Pentixafor(CPCR4-2)
Featured
|
Pentixafor is a synthetic, cyclic pentapeptide analog of stromal cell-derived factor-1 (SDF-1 or CXCL12), which is the natural ligand for the C-X-C chemokine receptor type 4 (CXCR4). CXCR4 is a chemokine receptor that plays a critical role in tumor growth, progression, invasiveness, and metastasis. Pentixafor is designed to target CXCR4, which is overexpressed in various cancers and is associated with poor differentiation and aggressive disease. |
|
| DC65339 |
HBED-CC-tris（tBu) ester
Featured
|
|
|
| DC65340 |
UAMC1110-NH2
Featured
|
UAMC1110-NH2 is a derivative of UAMC1110 (SP-13786) with an aminobutoxy group, making it a useful intermediate for synthesizing UAMC1110 conjugates. UAMC1110 is a potent and selective FAP inhibitor with low nanomolar potency and high specificity over related proteases. Together, UAMC1110-NH2 and UAMC1110 have significant potential for advancing FAP-targeted therapies, imaging agents, and research tools, particularly in cancer and fibrotic diseases.
|
|
| DC65709 |
PS-13 precursor 19
Featured
|
PS-13 Precursor 19 is a critical intermediate in the synthesis of PS-13, a highly potent and selective COX-1 inhibitor. PS-13's exceptional selectivity for COX-1 over COX-2 makes it a promising compound for both therapeutic development and research applications focused on understanding COX-1-mediated processes. |
|
| DC65710 |
PS13
Featured
|
PS13 is a highly potent and selective COX-1 inhibitor, and its radiolabeled form, [¹¹C]PS13, is a promising PET radiotracer for imaging COX-1 expression in vivo. Its ability to selectively bind COX-1 in major organs, including the spleen, gastrointestinal tract, kidneys, and brain, makes it a valuable tool for studying COX-1-mediated processes in health and disease. This radiotracer has significant potential for advancing research and therapeutic development in COX-1-related conditions. |
|
| DC65839 |
MC1 Precursor
Featured
|
Precursor of MC1, is a vital component in the synthesis of MC1, a selective and potent COX-2 inhibitor. Radiolabeled MC1, [¹¹C]MC1, serves as a promising PET radioligand for imaging COX-2 expression in vivo. Its high selectivity, combined with its ability to non-invasively visualize COX-2 in disease states, makes it a valuable tool for research and clinical applications, particularly in neuroinflammation, cancer, and drug development. |
|
| DC65841 |
MC1
Featured
|
MC1 is a selective and potent COX-2 inhibitor, and its radiolabeled form, [¹¹C]MC1, is a promising PET radiotracer for detecting COX-2 expression in vivo. Its ability to visualize COX-2 in neuroinflammation and other disease states makes it a valuable tool for research and therapeutic development, particularly in understanding and targeting COX-2-mediated processes in the brain.
|
|
| DC66114 |
FAPI-46
Featured
|
FAPI-46 is a highly promising FAP-targeted radiotracer with superior tumor uptake and prolonged accumulation, making it an excellent tool for imaging a wide range of cancers. Its versatility, combined with its potential for theragnostic applications, positions FAPI-46 as a valuable asset in the field of oncology, enabling improved diagnosis, staging, and treatment monitoring for patients with FAP-expressing tumors. |
|
| DC60607 |
SL-25.1188
Featured
|
SL-25.1188 is a reversible MAO-B inhibitor with high brain uptake and slow plasma metabolism, making it a promising candidate for treating Alzheimer's dementia and aiding in smoking cessation. Its ability to modulate neurotransmitter levels in the brain positions it as a valuable therapeutic tool for addressing these challenging conditions. |
|
| DC66458 |
FAPI -14
Featured
|
|
|
| DC60608 |
SL25.1188 precursor
Featured
|
SL25.1188 Precursor is a key intermediate in the synthesis of SL25.1188, a reversible and selective MAO-B radioligand. The radiolabeled form, [¹¹C]SL25.1188, is a promising PET imaging agent for studying MAO-B in the brain, with applications in neurodegenerative disease research and drug development. Its reversible binding and high selectivity make it a valuable tool for understanding MAO-B's role in health and disease. |
|
| DC66459 |
NOTA-FAPI
Featured
|
NOTA-FAPI is a FAP-targeted imaging probe with excellent tumor detection efficacy and imaging quality. Its high specificity for FAP, stable radiolabeling, and ability to visualize the tumor stroma make it a promising tool for tumor diagnosis, staging, and treatment monitoring. NOTA-FAPI has significant potential for advancing cancer imaging and therapy, particularly in cancers with a prominent stromal component. |
|
| DC66460 |
FAPI-4
Featured
|
FAPI-4 is a potent FAP inhibitor with significant applications in cancer research and diagnostics. Its radiolabeled form, ⁶⁸Ga-FAPI-4, is a promising PET/CT imaging agent for visualizing FAP-expressing tumors with excellent tumor-to-background contrast. This makes it a valuable tool for cancer diagnosis, staging, treatment monitoring, and therapeutic development, particularly in cancers with a prominent stromal component. |
|
| DC66461 |
SH-FAPI-4
Featured
|
SH-FAPI-4 is a specific fibroblast activation protein inhibitor (FAPI) compound that belongs to the FAPI family of molecules. SH-FAPI-4 is expected to selectively accumulate in FAP-positive tumors and disrupt the functions of cancer-associated fibroblasts (CAFs) within the tumor microenvironment. By inhibiting FAP activity, this compound aims to potentially slow tumor growth, enhance the efficacy of other cancer treatments, and modulate the tumor microenvironment. |
|
| DC66462 |
HYINC-FAPI-4
Featured
|
HYINC-FAPI-4 is a 99mTc-labeled derivative of fibroblast activation protein inhibitor (FAPI), specifically designed for single-photon emission computed tomography (SPECT) imaging of tumors expressing fibroblast activation protein (FAP). FAP is a key marker in the tumor stroma, which plays a critical role in tumor growth, invasion, and metastasis. |
.gif)
|
| DC66463 |
FAPI-46-NOTA
Featured
|
NOTA-FAPI-46 is an analogue of FAPI-46 (MedKoo Cat#207189). NOTA-FAPI-46 is useful in the diagnosis or treatment of a disease characterized by overexpression of fibroblast activation protein (FAP). NOTA-FAPI-46 can be used as a PET tracer for detection of diseases or disorders related to fibroblast activation protein. |
|
| DC66464 |
3BP-3940
Featured
|
3BP-3940 is a highly potent FAP-targeting peptide with significant potential in theranostics. Its ability to be coupled with diagnostic and therapeutic radionuclides makes it a versatile tool for tumor imaging, targeted therapy, and treatment monitoring. By focusing on the tumor stroma, 3BP-3940 offers a promising approach to improving cancer diagnosis and treatment, particularly for cancers with prominent stromal involvement. As research progresses, 3BP-3940 could play a key role in advancing precision oncology. |
|
| DC66465 |
Pentanedioate
Featured
|
Pentanedioate is a valuable starting material for the synthesis of PSMA inhibitors due to its flexible structure and functional groups that mimic natural PSMA ligands. By leveraging its chemical properties, researchers can develop potent and selective PSMA-targeting agents for diagnostic imaging, targeted therapy, and theranostic applications in prostate cancer and other PSMA-expressing malignancies. Its role in drug discovery highlights the importance of simple organic molecules in the development of advanced cancer therapies. |
|
| DC66467 |
F-PSMA 1007
Featured
|
|
|
| DC66468 |
NOTA-octreotide
Featured
|
NOTA-octreotide is a ligand for making [18F]AlF-NOTA-octreotide, which is a PET/CT imaging agent for somatostatin receptor imaging in neuroendocrine tumor patients |
|
